Login here
Register Free
MENU
October 24th, 11:00AM - 2:00PM US Eastern Time || October 24th, 7:00PM - 10:00PM US Eastern Time

Optimizing Heparin Management Strategies to Improve Patient Outcomes

This symposium will focus on the use of heparin management strategies to optimize patient outcomes. Implementation of the Anti-Xa assay for heparin monitoring and heparin-related complications will be covered.
 
Session Overview
  • Diagnosis: Introduction and Uses of Heparin 
  • aPTT vs. Anti-Xa Assays for Heparin Monitoring 
  • Heparin-Induced Thrombocytopenia (HIT)
 
Objectives
  • Discuss the clinical utility of using Anti-Xa testing for unfractionated heparin monitoring.
  • Highlight the health economic benefits of utilizing Anti-Xa versus aPTT testing for heparin monitoring. 
  • Discuss the diagnosis and management of heparin-induced thrombocytopenia, with case examples.
 
To accommodate time zones around the world, this program is offered at multiple times. Please select the program and time that is best for you.
Speakers
  • Presenter headshot of deepa_jayakody_arachchillage

    Deepa Jayakody Arachchillage, MD, MBBS, MRCP, FRCPath

    Imperial College London; Hammersmith Hospital, London, United Kingdom
  • Presenter headshot of k_maria_notini

    K. Maria Notini, MT (ASCP)

    Duke University Medical Center, Durham, NC, United States
  • Presenter headshot of ted_e_warkentin

    Ted E. Warkentin, MD, BSc (Med), FRCP(C), FACP

    McMaster University; Hamilton General Hospital, Hamilton, ON, Canada
  • Presenter headshot of annie_winkler

    Annie Winkler, MD

    Werfen, Bedford, MA, United States
Spanish

Nos complace invitarle a asistir a este simposio virtual. Los ponentes presentarán estrategias para la gestión del tratamiento con heparina para la optimización del cuidado del paciente, utilizando diversas pruebas de laboratorio. También se abordará la inclusión del ensayo anti-Xa para el control del tratamiento con heparina y las posibles complicaciones relacionadas con este tratamiento.
 
Descripción general de la sesión:
  • Diagnóstico: introducción y aplicaciones del tratamiento con heparina.
  • Aplicaciones del ensayo APTT vs. Anti-Xa para monitorizar el tratamiento con heparina
  • Trombocitopenia inducida por heparina (HIT)

 

Objetivos:
  • Debatir los beneficios de utilizar la prueba Anti-Xa para monitorizar el tratamiento con heparina
  • Resaltar los beneficios económicos que impactan en el sistema sanitario asociados al uso de la prueba Anti-Xa vs. APTT para el control del tratamiento con heparina
  • Debatir el diagnóstico y el manejo de los pacientes con HIT con casos clínicos
 
Para adaptarse a las zonas horarias de todo el mundo, este programa se ofrece en varios horarios. Por favor, seleccione el programa y el horario que se adapte mejor a sus necesidades.
Speakers
  • Presenter headshot of deepa_jayakody_arachchillage

    Deepa Jayakody Arachchillage, MD, MBBS, MRCP, FRCPath

    Imperial College London; Hammersmith Hospital, London, United Kingdom
  • Presenter headshot of k_maria_notini

    K. Maria Notini, MT (ASCP)

    Duke University Medical Center, Durham, NC, United States
  • Presenter headshot of ted_e_warkentin

    Ted E. Warkentin, MD, BSc (Med), FRCP(C), FACP

    McMaster University; Hamilton General Hospital, Hamilton, ON, Canada
  • Presenter headshot of annie_winkler

    Annie Winkler, MD

    Werfen, Bedford, MA, United States

Resources

CLICK HERE TO EMAIL LABROOTS HELP DESK